Department of Orthopaedics and Traumatology, Instituto Prevent Senior, São Paulo, Brazil.
Instituto Vita, São Paulo, Brazil.
Bone Joint J. 2024 Oct 1;106-B(10):1093-1099. doi: 10.1302/0301-620X.106B10.BJJ-2024-0342.R2.
A local injection may be used as an early option in the treatment of Morton's neuroma, and can be performed using various medications. The aim of this study was to compare the effects of injections of hyaluronic acid compared with corticosteroid in the treatment of this condition.
A total of 91 patients were assessed for this trial, of whom 45 were subsequently included and randomized into two groups. One patient was lost to follow-up, leaving 22 patients (24 feet) in each group. The patients in the hyaluronic acid group were treated with three ultrasound-guided injections (one per week) of hyaluronic acid (Osteonil Plus). Those in the corticosteroid group were treated with three ultrasound-guided injections (also one per week) of triamcinolone (Triancil). The patients were evaluated before treatment and at one, three, six, and 12 months after treatment. The primary outcome measure was the visual analogue scale for pain (VAS). Secondary outcome measures included the American Orthopaedic Foot and Ankle Society (AOFAS) score, and complications.
Both groups showed significant improvement in VAS and AOFAS scores (p < 0.05) after 12 months. The corticosteroid group had a significantly greater reduction in VAS and increase in AOFAS scores compared with the hyaluronic acid group, at one, three, and six months, but with no significant difference at 12 months. There were no complications in the hyaluronic acid group. There were minor local complications in six patients (six feet) (25.0%) in the corticosteroid group, all with discolouration of the skin at the site of the injection. These minor complications might have been due to the three weekly injections of a relatively high dose of corticosteroid. No patient subsequently underwent excision of the neuroma.
An ultrasound-guided corticosteroid injection showed statistically significantly better functional and pain outcomes than an ultrasound-guided injection of hyaluronic acid for the treatment of a Morton's neuroma at many timepoints. Thus, a corticosteroid injection should be regarded as a primary option in the treatment of these patients, and the only indication for an injection of hyaluronic acid might be in patients in whom corticosteroid is contraindicated.
局部注射可能是治疗莫顿神经瘤的早期选择,可使用各种药物进行。本研究的目的是比较透明质酸注射与皮质类固醇注射治疗这种疾病的效果。
共有 91 名患者接受了此项试验评估,其中 45 名随后被纳入并随机分为两组。1 名患者失访,每组各有 22 名患者(24 只脚)。透明质酸组的患者接受了三次超声引导的透明质酸(Osteonil Plus)注射(每周一次)。皮质类固醇组的患者接受了三次超声引导的皮质类固醇(Triancil)注射(也是每周一次)。患者在治疗前和治疗后 1、3、6 和 12 个月进行评估。主要观察指标为疼痛视觉模拟评分(VAS)。次要观察指标包括美国矫形足踝协会(AOFAS)评分和并发症。
两组患者在治疗 12 个月后 VAS 和 AOFAS 评分均显著改善(p < 0.05)。与透明质酸组相比,皮质类固醇组在 1、3 和 6 个月时 VAS 显著降低,AOFAS 评分显著升高,但在 12 个月时无显著差异。透明质酸组无并发症。皮质类固醇组有 6 名患者(6 只脚)(25.0%)出现轻微局部并发症,均表现为注射部位皮肤变色。这些轻微并发症可能是由于每周三次注射相对高剂量的皮质类固醇所致。没有患者随后行神经瘤切除术。
与超声引导透明质酸注射相比,超声引导皮质类固醇注射在许多时间点治疗莫顿神经瘤的功能和疼痛结果均具有统计学意义上的显著优势。因此,皮质类固醇注射应被视为这些患者的主要治疗选择,而仅在皮质类固醇禁忌的情况下才考虑注射透明质酸。